Classification
- Anatomical main groupLAntineoplastic and immunomodulating agents
- Therapeutic subgroupL04
- Pharmacological subgroupL04A
- Chemical subgroupL04AG
- Chemical substanceL04AG12Ofatumumab
Where it is registered
Each register and historical list with its number of registrations and a few of them.
Canada
Health Canada · 4 registrations
- Kesimpta20 MG / 0.4 ML · Solution · Novartis Pharmaceuticals Canada INC · Marketed
- Kesimpta20 MG / 0.4 ML · Solution · Novartis Pharmaceuticals Canada INC · Authorised
- Arzerra100 MG / 5 ML · Solution · Novartis Pharmaceuticals Canada INC
- Arzerra1000 MG / 50 ML · Solution · Novartis Pharmaceuticals Canada INC
United States
FDA · 4 registrations
At a glance
- ATC code
- L04AG12
- Registers
- 9
- Historical lists
- 1
- Registrations
- 24
- With their own page
- 16
- Companies
- 9
All medicines with Ofatumumab
Human medicines from every register that match Ofatumumab by substance or by name, a page at a time, so the count can differ from the registrations above. Strengths and packs are on each medicine’s page.
24 search results
| Medicine | Register | Strength | Form | Status | Holder |
|---|---|---|---|---|---|
| Arzerra | United States | 100MG/5ML | injectable | Marketed | Novartis |
| Kesimpta | United States | 20MG/0.4ML | solution | Marketed | Novartis |
| Kesimpta | United States | 20MG/0.4ML | Injection | Marketed | Novartis Pharmaceuticals Corporation |
| Kesimpta | United States | 20MG/0.4ML | Injection | Not marketed | Novartis Pharmaceuticals Corporation |
| KESIMPTA 20 mg SOLUCION INYECTABLE EN PLUMA PRECARGADA | Spain | 20 mg | solución inyectable en pluma precargada | Marketed | Novartis Europharm Limited |
| Kesimpta | European Union | Authorised | Novartis Europharm Limited | ||
| Kesimpta 20 mg, oplossing voor injectie in voorgevulde pen | Netherlands | Oplossing voor injectie | Authorised | Novartis Europharm Limited | |
| Kesimpta 20 mg, oplossing voor injectie in voorgevulde spuit | Netherlands | Oplossing voor injectie | Authorised | Novartis Europharm Limited | |
| Kesimpta 20 MG Solucion Inyectable en Pluma Precargada | Spain | 20 mg | solución inyectable en pluma precargada | Authorised | Novartis Europharm Limited |
| Kesimpta | Canada | 20 MG / 0.4 ML | Solution | Marketed | Novartis Pharmaceuticals Canada INC |
| Kesimpta | Brazil | Authorised | Novartis Biociencias S.A | ||
| Kesimpta | Canada | 20 MG / 0.4 ML | Solution | Authorised | Novartis Pharmaceuticals Canada INC |
| Kesimpta® | Serbia | 20mg | rastvor za injekciju u napunjenom injekcionom penu | Authorised | PredstavniŠTvo Novartis Pharma Services INC. Beograd (Novi Beograd) |
| Kesimpta Solution for Injection in Pre-Filled Pen 20MG/0.4ML | Singapore | 20mg/0.4ml | injection, solution | Authorised | Novartis (Singapore) Pte LTD |
| Kesimpta Solution for Injection in Pre-Filled Syringe 20MG/0.4ML | Singapore | 20mg/0.4ml | injection, solution | Authorised | Novartis (Singapore) Pte LTD |
| Kesimpta | Croatia | Marketed | |||
| Arzerra | Saudi Arabia | Authorised | Glaxo Operation | ||
| Arzerra | Saudi Arabia | Authorised | Glaxo Operation | ||
| Kesimpta | Saudi Arabia | Authorised | NOVARTIS Pharma Stein AG | ||
| Arzerra | European Union | Withdrawn | Novartis Europharm Ltd | ||
| Arzerra | Canada | 1000 MG / 50 ML | Solution | Cancelled | Novartis Pharmaceuticals Canada INC |
| Arzerra | Brazil | Cancelled | Novartis Biociencias S.A | ||
| Arzerra | Brazil | Cancelled | Glaxosmithkline Brasil Ltda | ||
| Arzerra | Canada | 100 MG / 5 ML | Solution | Cancelled | Novartis Pharmaceuticals Canada INC |